Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has created a world-class oncology advisory board. The board will include key opinion leaders from several nationally recognized institutions. Board members include Philip A. Philip, MD, PhD, from the Henry Ford Cancer Institute; Mitesh Borad, MD, from the Mayo Clinic; Patrick Boland, MD, from Rutgers Cancer Institute; Howard Hochster, MD, FACP, from Rutgers Cancer Institute; and Sunil Sharma, MD, FACP, from the Translational Genomics (TGen) Research Institute. “As we continue development of our next generation chemotherapy (‘NGC’) products, it is important that we rely on the guidance of the most respected advisors in the field,” said Processa Pharmaceuticals founder and chief development and regulatory officer Sian Bigora, PharmD, in the press release. “We are excited about the formation of our advisory board and grateful to its respected members for their dedication toward optimizing patient care with new drugs that are distributed preferentially to cancer cells and metabolized more efficiently to molecules that have been proven to kill cancer. We expect that these NGC drugs will improve the treatment of cancer by improving not only the safety and efficacy in cancer patients, but they will also allow for more cancer patients to be treated given the improved safety-efficacy profile.”
To view the full press release, visit https://ibn.fm/EpqLZ
About Processa Pharmaceuticals Inc.
Processa is a clinical-stage pharmaceutical company focused on developing next-generation chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also will increase the probability of FDA approval for its next-generation chemotherapy drugs. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug-development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, the company has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGC drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each NGC drug. Currently in the company pipeline are three NGC drugs: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers).
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
